GABAergic neuroactive steroid response to sertraline in premenstrual dysphoric disorder.

ABSTRACT:

Rationale

Premenstrual dysphoric disorder (PMDD) affects approximately 5% of menstruating individuals, with significant negative mood symptoms in the luteal phase of the menstrual cycle. PMDD's pathophysiology and treatment mechanisms are poorly characterized, but may involve altered neuroactive steroid function in the brain. Selective serotonin reuptake inhibitors (SSRIs), a first-line PMDD treatment, reportedly alter gamma-aminobutyric acid (GABA)ergic neuroactive steroid levels in PMDD.

Aims

The aims of this study were to determine whether the SSRI sertraline increased serum levels of neuroactive steroids that modulate the effect of GABA at GABA-A receptors (GABAAR) and if so, whether an increase was associated with improvement in PMDD symptoms.

Methods

Participant

SUBMITTER: Miller KN 

PROVIDER: S-EPMC10846389 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature